FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806183053> ?p ?o ?g. }

• W2806183053 endingPage "84" @default.
• W2806183053 startingPage "72" @default.
• W2806183053 abstract "Emerging Therapeutic Options for Hepatitis C Treatment options for dual HCV/HBV coinfectionChun-Jen Liu & Jia-Horng KaoChun-Jen LiuChun-Jen Liu received his PhD from the Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine (Taipei, Taiwan). He is now a Professor at this institute. He is interested in the field of chronic hepatitis B and C, and nonalcoholic fatty liver disease. His studies focus on the role of viral and host factors in the pathogenesis and natural/treatment outcomes of chronic hepatitis B and C. In addition, he is actively involved in clinical trials on the treatment of chronic viral hepatitis and hepatocellular carcinoma. He has published more than 150 peer-reviewed papers.Search for more papers by this author & Jia-Horng KaoJia-Horng Kao, distinguished Professor of Medicine at the National Taiwan University, was Director of the Hepatitis Research Centre at the National Taiwan University Hospital, Taipei, from 2003 to 2009 and is now Director of the Graduate Institute of Clinical Medicine at the National Taiwan University. He is Editor of the Journal of Gastroenterology and Hepatology as well as Associate Editor for Hepatology International, and serves on the editorial board of the Journal of Hepatology and Journal of Infectious Diseases. His research interests include the pathogenic role of viral and host factors in the natural history and treatment outcomes of chronic hepatitis B and C. He also actively participates in clinical trials for the treatment of chronic hepatitis B and C. As of August 2012, he has published more than 300 articles, with 7536 citations and a H-index of 43.Search for more papers by this authorPublished Online:15 May 2013https://doi.org/10.2217/ebo.12.276AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: Dual hepatitis C virus (HCV)/hepatitis B virus (HBV) infection is not uncommon in HCV- or HBV-endemic areas. However, several clinical and pathogenic issues remain to be resolved. First, clinical and in vitro studies suggest that there may be interactions between the two viruses. The dynamics of viral interactions in untreated versus treated settings, and their influence on the long-term outcomes and treatment options in patients with dual HCV/HBV infection, await further studies. Second, combined pegylated IFN-α2a plus ribavirin is effective for the treatment of hepatitis B surface antigen-positive patients that are chronically infected with active hepatitis C, the treatment outcomes being similar to patients with HCV monoinfection. Notably, approximately 30% of dually infected patients with baseline undetectable serum HBV DNA levels develop HBV reactivation after the start of treatment. How to prevent and treat HBV reactivation in this special clinical setting should be clarified. Furthermore, approximately 10% of dually infected patients lost hepatitis B surface antigen at the end of combination therapy, and the mechanisms need further investigations. Finally, the optimal treatment strategies for hepatitis B e antigen-positive dually infected patients should be explored in future clinical trials. References1 Liu CJ , Liou JM , Chen DS et al. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections . J. Formos Med. Assoc. 104 , 783 – 791 (2005) . Medline, Google Scholar2 Liu CJ , Chen PJ , Chen DS . Dual chronic hepatitis B virus and hepatitis C virus infection . Hepatol. Int. 3 , 517 – 525 (2009) . Crossref, Medline, Google Scholar3 Sagnelli E , Coppola N , Messina V et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course . Hepatology 36 , 1285 – 1291 (2002) . Crossref, Medline, Google Scholar4 Liaw YF , Chen YC , Sheen IS et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection . Gastroenterology 126 , 1024 – 1029 (2004) . Crossref, Medline, Google Scholar5 Donato F , Boffetta P , Puoti M . A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma . Int. J. Cancer 75 , 347 – 354 (1998) . Crossref, Medline, CAS, Google Scholar6 Huang YT , Jen CL , Yang HI et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C . J. Clin. Oncol. 29 , 3643 – 3650 (2011) . Crossref, Medline, Google Scholar7 Liu CJ , Chuang WL , Lee CM et al. An open label, comparative, multicenter study of peginterferon alfa-2a plus ribavirin in the treatment of patients with chronic hepatitis C/hepatitis B co-infection versus those with chronic hepatitis C monoinfection . Gastroenterology 136 , 496 – 504 (2009) . Crossref, Medline, CAS, Google Scholar8 Potthoff A , Wedemeyer H , Boecher WO et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection . J. Hepatol. 49 , 688 – 694 (2008) . Crossref, Medline, CAS, Google Scholar9 Bellecave P , Gouttenoire J , Gajer M et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference . Hepatology 50 , 46 – 55 (2009) . Crossref, Medline, CAS, Google Scholar10 Raimondo G , Brunetto MR , Pontisso P et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients . Hepatology 43 , 100 – 107 (2006) . Crossref, Medline, Google Scholar11 Chu CM , Yeh CT , Liaw YF . Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection . J. Clin. Microbiol. 36 , 2084 – 2086 (1998) . Crossref, Medline, CAS, Google Scholar12 Villa E , Grottola A , Buttafoco P et al. High doses of α-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial . Am. J. Gastroenterol. 96 , 2973 – 2977 (2001) . Medline, CAS, Google Scholar13 Liu CJ , Chen PJ , Lai MY , Kao JH , Jeng YM , Chen DS . Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients . Hepatology 37 , 568 – 576 (2003) . Crossref, Medline, CAS, Google Scholar14 Chuang WL , Dai CY , Chang WY et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-α plus ribavirin combination therapy . Antivir. Ther. 10 , 125 – 133 (2005) . Medline, CAS, Google Scholar15 Hung CH , Lee CM , Lu SN et al. Combination therapy with interferon-α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection . J. Gastroenterol. Hepatol. 20 , 727 – 732 (2005) . Crossref, Medline, CAS, Google Scholar16 Kim YJ , Lee JW , Kim YS et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus . Korean J. Hepatol. 17 , 199 – 205 (2011) . Crossref, Medline, Google Scholar17 Masao Omata , Tatsuo Kanda , Ming-Lung Yu et al. APASL consensus statements and management algorithms for hepatitis C virus infection . Hepatol. Int. 6 , 409 – 435 (2012) . Crossref, Medline, Google Scholar18 European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection . J. Hepatol. 55 , 245 – 264 (2011) . Crossref, Medline, Google Scholar19 Marrone A , Zampino R , D’Onofrio M , Ricciotti R , Ruggiero G , Utili R . Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection . J. Hepatol. 41 , 1064 – 1065 (2004) . Crossref, Medline, CAS, Google Scholar20 Coppola N , Stanzione M , Messina V et al. Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection . J. Viral. Hepat. 19 (12) , 890 – 896 (2012) . Crossref, Medline, CAS, Google Scholar21 Guptan RC , Thakur V , Raina V , Sarin SK . Alpha-interferon therapy in chronic hepatitis due to active dual infection with hepatitis B and C viruses . J. Gastroenterol. Hepatol. 14 , 893 – 898 (1999) . Crossref, Medline, CAS, Google Scholar22 Gehenot M , Marcellin P , Colin JF , Martinot M , Benhamou JP , Erlinger S . Alpha interferon therapy in HBsAg positive patients with chronic hepatitis C . Hepatology 22 , 116A (1995) . Crossref, Google Scholar23 Utili R , Zampino R , Bellopede P et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment . Blood 94 , 4046 – 4052 (1999) . Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Emerging Therapeutic Options for Hepatitis CMetrics Downloaded 10 times History Published online 15 May 2013 Published in print May 2013 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2806183053 created "2018-06-13" @default.
• W2806183053 creator A5063550464 @default.
• W2806183053 creator A5072593323 @default.
• W2806183053 date "2013-05-01" @default.
• W2806183053 modified "2023-10-18" @default.
• W2806183053 title "Treatment options for dual HCV/HBV coinfection" @default.
• W2806183053 cites W184425049 @default.
• W2806183053 cites W1895295453 @default.
• W2806183053 cites W1986492786 @default.
• W2806183053 cites W1989448136 @default.
• W2806183053 cites W1990466254 @default.
• W2806183053 cites W2010509888 @default.
• W2806183053 cites W2014841486 @default.
• W2806183053 cites W2056827569 @default.
• W2806183053 cites W2083179081 @default.
• W2806183053 cites W2095545746 @default.
• W2806183053 cites W2098240472 @default.
• W2806183053 cites W2103116252 @default.
• W2806183053 cites W2117380333 @default.
• W2806183053 cites W2138465984 @default.
• W2806183053 cites W2141353331 @default.
• W2806183053 cites W2148345648 @default.
• W2806183053 cites W2155893993 @default.
• W2806183053 cites W2164385547 @default.
• W2806183053 cites W2237084078 @default.
• W2806183053 cites W4211077792 @default.
• W2806183053 doi "https://doi.org/10.2217/ebo.12.276" @default.
• W2806183053 hasPublicationYear "2013" @default.
• W2806183053 type Work @default.
• W2806183053 sameAs 2806183053 @default.
• W2806183053 citedByCount "0" @default.
• W2806183053 crossrefType "other" @default.
• W2806183053 hasAuthorship W2806183053A5063550464 @default.
• W2806183053 hasAuthorship W2806183053A5072593323 @default.
• W2806183053 hasConcept C138885662 @default.
• W2806183053 hasConcept C159047783 @default.
• W2806183053 hasConcept C2776455275 @default.
• W2806183053 hasConcept C2777813720 @default.
• W2806183053 hasConcept C2780980858 @default.
• W2806183053 hasConcept C3013748606 @default.
• W2806183053 hasConcept C41895202 @default.
• W2806183053 hasConcept C71924100 @default.
• W2806183053 hasConceptScore W2806183053C138885662 @default.
• W2806183053 hasConceptScore W2806183053C159047783 @default.
• W2806183053 hasConceptScore W2806183053C2776455275 @default.
• W2806183053 hasConceptScore W2806183053C2777813720 @default.
• W2806183053 hasConceptScore W2806183053C2780980858 @default.
• W2806183053 hasConceptScore W2806183053C3013748606 @default.
• W2806183053 hasConceptScore W2806183053C41895202 @default.
• W2806183053 hasConceptScore W2806183053C71924100 @default.
• W2806183053 hasLocation W28061830531 @default.
• W2806183053 hasOpenAccess W2806183053 @default.
• W2806183053 hasPrimaryLocation W28061830531 @default.
• W2806183053 hasRelatedWork W2006204925 @default.
• W2806183053 hasRelatedWork W2073155785 @default.
• W2806183053 hasRelatedWork W2101028918 @default.
• W2806183053 hasRelatedWork W2409319833 @default.
• W2806183053 hasRelatedWork W2508311838 @default.
• W2806183053 hasRelatedWork W2905528513 @default.
• W2806183053 hasRelatedWork W2914910499 @default.
• W2806183053 hasRelatedWork W3083114193 @default.
• W2806183053 hasRelatedWork W4231704069 @default.
• W2806183053 hasRelatedWork W4241448222 @default.
• W2806183053 isParatext "false" @default.
• W2806183053 isRetracted "false" @default.
• W2806183053 magId "2806183053" @default.
• W2806183053 workType "other" @default.